GT Biopharma, a company that develops novel immuno-oncology biopharmaceutical drugs, is looking to be listed on the Nasdaq. The company is currently listed on the Over-the-Counter Markets under the ticker symbol "GTBP." It hopes to trade on the Nasdaq under the same ticker symbol.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.34 |
|---|---|
| 52-week range | $1.72 - $10.66 |
| 50-day moving average | $2.33 |
| 200-day moving average | $2.45 |
| Wall St. target price | $11.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-6.94 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.375 from 2025-05-07
| 1 week (2025-05-01) | -3.06% |
|---|---|
| 1 month (2025-04-09) | 7.95% |
| 3 months (2025-02-07) | 10.47% |
| 6 months (2024-11-08) | -28.68% |
| 1 year (2024-05-09) | -26.43% |
|---|---|
| 2 years (2023-05-08) | -73.61% |
| 3 years (2022-05-06) | 49.8 |
| 5 years (2020-05-08) | 70.3799 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -97.89% |
| Return on equity TTM | -453.39% |
| Profit margin | 0% |
| Book value | $-0.75 |
| Market Capitalization | $6.2 million |
TTM: trailing 12 months
We're not expecting Gt Biopharma Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Gt Biopharma Inc's shares were split on a 1:30 basis on 4 February 2024 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Gt Biopharma Inc shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Gt Biopharma Inc shares which in turn could have impacted Gt Biopharma Inc's share price.
Over the last 12 months, Gt Biopharma Inc's shares have ranged in value from as little as $1.72 up to $10.6599. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gt Biopharma Inc's is 1.315. This would suggest that Gt Biopharma Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Gt Biopharma Inc's beta into context you can compare it against those of similar companies.
GT Biopharma, Inc. , a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.